Search Page

1

Cite

Share

Overview and diagnosis of multiple sclerosis.

Hunter SF. Hunter SF. Am J Manag Care. 2016 Jun;22(6 Suppl):s141-50. Am J Manag Care. 2016. PMID: 27356023 Free article. Review.

Cite

Share

2

Cite

Share

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.

Chun J, Giovannoni G, Hunter SF. Chun J, et al. Among authors: hunter sf. Drugs. 2021 Feb;81(2):207-231. doi: 10.1007/s40265-020-01431-8. Drugs. 2021. PMID: 33289881 Free PMC article. Review.

Cite

Share

3

Cite

Share

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.

Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, Bowen JD, Negroski D, Naismith RT, Hunter SF, Gudesblatt M, Chen H, Lyons J, Shankar SL, Kapadia S, Mendoza JP, Singer BA. Wray S, et al. Among authors: hunter sf. Adv Ther. 2022 Apr;39(4):1810-1831. doi: 10.1007/s12325-022-02068-7. Epub 2022 Feb 24. Adv Ther. 2022. PMID: 35211872 Free PMC article. Clinical Trial.

Cite

Share

4

Cite

Share

Optic neuritis: Both eyes improve after corticotropin.

Hunter SF, Calkwood J, Kantor D. Hunter SF, et al. J Neurol Sci. 2019 Dec 15;407:116504. doi: 10.1016/j.jns.2019.116504. Epub 2019 Oct 31. J Neurol Sci. 2019. PMID: 31753511 No abstract available.

Cite

Share

5

Cite

Share

Rational clinical immunotherapy for multiple sclerosis.

Hunter SF, Weinshenker BG, Carter JL, Noseworthy JH. Hunter SF, et al. Mayo Clin Proc. 1997 Aug;72(8):765-80. doi: 10.1016/S0025-6196(11)63598-2. Mayo Clin Proc. 1997. PMID: 9276606 Review.

Cite

Share

6

Cite

Share

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.

Hunter SF, Bindra J, Chopra I, Niewoehner J, Panaccio MP, Wan GJ. Hunter SF, et al. Clinicoecon Outcomes Res. 2021 Oct 11;13:883-892. doi: 10.2147/CEOR.S330118. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 34675568 Free PMC article.

Cite

Share

7

Cite

Share

Implications for multiple sclerosis in the era of the Affordable Care Act: a clinical overview.

Maroney M, Hunter SF. Maroney M, et al. Among authors: hunter sf. Am J Manag Care. 2014 Dec;20(11 Suppl):S220-7. Am J Manag Care. 2014. PMID: 25734887 Free article. Review.

Cite

Share

8

Cite

Share

Implications for multiple sclerosis in the era of the Affordable Care Act: an evolving treatment paradigm.

Brunetti L, Hunter SF. Brunetti L, et al. Among authors: hunter sf. Am J Manag Care. 2014 Dec;20(11 Suppl):S228-41. Am J Manag Care. 2014. PMID: 25734888 Free article. Review.

Cite

Share

9

Cite

Share

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.

Hunter SF, Bowen JD, Reder AT. Hunter SF, et al. CNS Drugs. 2016 Feb;30(2):135-47. doi: 10.1007/s40263-015-0297-0. CNS Drugs. 2016. PMID: 26715391 Free PMC article. Review.

Cite

Share

10

Cite

Share

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.

Hunter SF, Aburashed RA, Alroughani R, Chan A, Dive D, Eichau S, Kantor D, Kim HJ, Lycke J, Macdonell RAL, Pozzilli C, Scott T, Sharrack B, Wiendl H, Chung L, Daizadeh N, Baker DP, Vermersch P; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Hunter SF, et al. Neurol Ther. 2021 Dec;10(2):803-818. doi: 10.1007/s40120-021-00262-3. Epub 2021 Jun 24. Neurol Ther. 2021. PMID: 34165694 Free PMC article.

Cite

Share